Search
SF Healthcare Week: Madrigal CEO Bill Sibold talks about the commercialization of the MASH treatment Rezdiffra, and two bolt on deals the company has done for combinations
He discusses the rationale behind acquiring a DGAT-2 and GLP-1, and how a non-pharma sized company has been able to succeed with a new drug launch.
Jan 14
The CEO of Madrigal on the launch of Rezdiffra for NASH liver disease
Bill Sibold describes how Madrigal has prepared for the launch and illustrates how the medicine is meant to impact disease progression.
Apr 10, 2024
Madrigal's CEO discusses the NASH field ahead of a key FDA decision date in March
Bill Sibold describes how resmetirom acts on fibrosis and could be the first commercial product in NASH.
Jan 9, 2024
.png){kind=logo}
